Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Acrivon Therapeutics

Request full access

Biotech company specializing in drug development through early clinical treatment success

Cambridge, United StatesFounded 2018Biotech & Life Sciences

About Acrivon Therapeutics

Acrivon Therapeutics is a clinical-stage oncology company focused on developing targeted therapies to improve the lives of cancer patients. Operating at the frontier of proteomics, Acrivon employs its proprietary precision medicine platform, Acrivon Predictive Precision Proteomics (AP3), to develop a robust drug pipeline. The AP3 platform generates OncoSignature companion diagnostics, which are designed to accurately identify patients whose tumors are predicted to be sensitive to Acrivon's drug candidates. This approach aims to revolutionize precision oncology drug development and treatment by ensuring that therapies are matched with patients who are most likely to benefit, regardless of underlying genetic tumor alterations. Acrivon serves patients suffering from various types of cancer, aiming to provide more effective and personalized treatment options. The company operates within the precision oncology market, which focuses on tailoring medical treatment to the individual characteristics of each patient's disease. Acrivon's business model involves the development and commercialization of its proprietary therapies and companion diagnostics, generating revenue through the sale of these products and potentially through partnerships and collaborations with other pharmaceutical companies.

Source: Dealroom company data

Acrivon Therapeutics in the Cambridge ecosystem

Live from Dealroom

The Acrivon Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

14 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A14 investors entered at this stage

Team profiled 12 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 4 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
4 countries with
team presence
🇺🇸 United States73.8%
🇮🇪 Ireland1.5%
🇮🇱 Israel1.5%
🇨🇦 Canada1.5%
4 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Acrivon Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Acrivon Therapeutics on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.